五洲医疗(301234) - 投资者关系活动记录表

Group 1: Business Impact and Performance - The impact of recent tariff adjustments on the company's business is limited, with revenue from exports to the U.S. not reaching a significant level [1] - The company has been focusing on enhancing its core business and R&D investments to improve product competitiveness and expand business channels [2] - The company's stock performance is influenced by external factors, including market conditions and investor preferences, despite efforts to optimize governance and enhance shareholder communication [2] Group 2: Financial Performance and Dividends - For the fiscal year 2024, the company plans to distribute a cash dividend of 3 RMB per 10 shares, totaling 20.4 million RMB, with cumulative cash dividends over the past three years amounting to 81.6 million RMB [2] - The company's operating profit increased year-on-year in the first quarter, but net profit declined due to global trade policy changes and increased operational costs [4] Group 3: Future Growth Drivers - The company aims to drive future profitability through innovation, optimizing existing products, and enhancing production efficiency [3] - There are currently 28 ongoing R&D projects, focusing on expanding the product line and entering new markets, including active medical devices [5]